Extensive impairment of triazolam and alprazolam clearance by short- term low-dose ritonavir: The clinical dilemma of concurrent inhibition and induction

Journal of Clinical Psychopharmacology

Volumn 19, Issue 4, 1999, Pages 293-296

  Greenblatt, D J ^a   Von Moltke, L L ^a   Daily, J P ^a   Harmatz, J S ^a   Shader, R I ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ANTIRETROVIRUS AGENT; CYTOCHROME P450; HYPNOTIC SEDATIVE AGENT; KETOCONAZOLE; NUCLEOSIDE ANALOG; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; TRIAZOLAM;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INHIBITION; DRUG METABOLISM; EDITORIAL; GLUCOSE INTOLERANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEINASE INHIBITION; QUALITY OF LIFE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ALPRAZOLAM; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INDUCTION; HIV PROTEASE INHIBITORS; HUMANS; HYPNOTICS AND SEDATIVES; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; OXIDOREDUCTASES, N-DEMETHYLATING; RITONAVIR; TRIAZOLAM;

EID: 0032789533     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199908000-00001     Document Type: Editorial

References (51)